Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
5-Fluorouracil versus mitomycin C as adjuncts to conjunctival autograft in preventing pterygium recurrence
International Ophthalmology, Volume 32, No. 1, Year 2012
Notification
URL copied to clipboard!
Description
To compare the efficacy of 5-fluorouracil (5-FU) with mitomycin C (MMC) in preventing pterygium recurrence when used as an adjuvant following pterygium excision with conjunctival autograft. Low-dose MMC combined with conjunctival autograft is an effective treatment for preventing recurrence following pterygium excision, but safety, cost, and availability limit its use in developing countries. There is a paucity of data on the efficacy of 5-FU when used in Africa as an adjuvant to conjunctival autograft following pterygium excision. This is a randomized controlled prospective trial using either 50 mg/ml 5-FU or 0.01% MMC. Eighty eyes of 80 subjects were studied. Forty-six subjects with a mean age 49.8 ± 13.8 years were treated with 5-FU (USD 13.0 per unit), while 34 patients with a mean age 51.9 ± 12.1 years were treated with MMC (USD 20.0 per unit). There was no significant difference in mean age between the two groups (p = 0.48). The ratio of male to female patients in both groups was similar at 0.92:1 for the 5-FU group and 1:1 for the MMC group (p = 0.85). Mean follow-up period was 35.2 ± 29.1 weeks. Recurrence rate in the 5-FU group was 8.7% compared to 11.8% in the MMC group (recurrence risk ratio = 0.71, 95% CI 0.17-3.1, p = 0.7). One patient from the MMC-treated group had corneoscleral melting. Other complications were mild and not sight threatening. In the prevention of pterygium recurrence, 5-FU appears to compare favorably with low-dose MMC when used as an adjuvant following pterygium excision and conjunctival autograft. Further studies are required to assess the long-term effect of using 5-FU in such cases. © 2012 Springer Science+Business Media B.V.
Authors & Co-Authors
Bekibele, Charles Obu
Nigeria, Ibadan
University College Hospital, Ibadan
Ashaye, Adeyinka Olusola
Nigeria, Ibadan
University College Hospital, Ibadan
Olusanya, Bolutife Ayokunnu
Nigeria, Ibadan
University College Hospital, Ibadan
Baiyeroju, Aderonke Mojisola
Nigeria, Ibadan
University College Hospital, Ibadan
Fasina, Oluyemi O.
Nigeria, Ibadan
University College Hospital, Ibadan
Ibrahim, Adekunmi O.
Nigeria, Ibadan
University College Hospital, Ibadan
Ogun, Olufunmilola Abimbola
Nigeria, Ibadan
University College Hospital, Ibadan
Statistics
Citations: 26
Authors: 7
Affiliations: 1
Identifiers
Doi:
10.1007/s10792-011-9509-x
ISSN:
01655701
Research Areas
Health System And Policy
Study Design
Cohort Study
Participants Gender
Male
Female